Early safety indicators of COVID-19 convalescent plasma in 5000 patients

BACKGROUND: Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatmen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Joyner, Michael J., Wright, R. Scott, Fairweather, DeLisa, Senefeld, Jonathon W., Bruno, Katelyn A., Klassen, Stephen A., Carter, Rickey E., Klompas, Allan M., Wiggins, Chad C., Shepherd, John R.A., Rea, Robert F., Whelan, Emily R., Clayburn, Andrew J., Spiegel, Matthew R., Johnson, Patrick W., Lesser, Elizabeth R., Baker, Sarah E., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Hodge, David O., Kunze, Katie L., Buras, Matthew R., Vogt, Matthew N.P., Herasevich, Vitaly, Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Paneth, Nigel S., Verdun, Nicole C., Marks, Peter, Casadevall, Arturo
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2020
Témata:
Clinical Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7456238/
https://ncbi.nlm.nih.gov/pubmed/32525844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI140200
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky